Theravance axes staff as lead pipeline drug flunks phase 3 trialTheravance has been forced to downsize its business after its lead pipeline drug ampreloxatine missed the mark in Share XTheravance axes staff as lead pipeline drug flunks phase 3 trialhttps://pharmaphorum.com/news/theravance-axes-staff-as-lead-pipeline-drug-flunks-phase-3-trial/
FDA rejects Sunovion’s nebulised COPD drugThe US regulator has rejected Sunovion’s nebulised therapy for chronic obstructive pulmonary disease (COPD), leaving the company struggling Share XFDA rejects Sunovion’s nebulised COPD drughttps://pharmaphorum.com/news/fda-rejects-sunovions-nebulised-copd-drug/
